Price | Negotiable |
MOQ | 1000 |
Delivery Time | 7 Days |
Brand | WWHS |
Place of Origin | CN |
Certification | ISO 13485, CE |
Model Number | CEA |
Packaging Details | Colorful Paper Box |
Payment Terms | L/C, T/T |
Supply Ability | 30000 Kits per Week |
Place of Origin | CN | Warranty | 12 Months |
Keywords | FIA POCT | Packaging Details | Colorful Paper Box |
Product Name | Carcinoembryonic Antigen | Throughput | 3000 Tests/Day |
Model Number | CEA | Supply Ability | 30000 Kits per Week |
Certification | ISO 13485, CE | Brand Name | WWHS |
Payment Terms | L/C, T/T | Reactivity | Human |
Storage | RT | Advantage | High Sensitivity |
Price | Negotiable | Delivery Time | 7 Days |
Minimum Order Quantity | 1000 | Manufacturer | WWHS Bio |
Package | 25 Tests | Application | Tumor Markers Diagnose |
【Product name】
Carcinoembryonic Antigen (CEA) Rapid Quantitative Test(Fluorescence immunoassay)
【Package specification】
25 Tests/kit
【Intended use】
This kit is used for quantitative determination of CEA in human whole blood, plasma and serum.
Carcinoembryonic antigen (CEA) is a tumor associated antigen, first described in 1965 by Gold and Freedman1. It is a cell-surface glycoprotein with a molecular weight of 180-200kD, that occurs in high levels in colon epithelial cells during embryonic development. Levels of CEA are significantly lower in colon tissue of adults, but can become elevated when inflammation or tumours arise in any endodermal tissue, including the gastrointestinal tract, respiratory tract, pancreas and breast.
An over expression of CEA protein has been detected in a variety of adenocarcinomas, including gastric, pancreatic, small intestine, colon, rectal, ovarian, breast, cervical and non-small-cell lung cancers. CEA is also expressed by epithelial cells in several non-malignant disorders, including diverticulitis, pancreatitis, inflammatory bowel disease, cirrhosis, hepatitis, bronchitis and renal failure and also in heavy smokers.
Therefore CEA should not be regarded as a tumour-specific marker for the screening of a general population for undetected cancers. However, the determination of CEA levels provides important information about patient prognosis, recurrence of tumours after surgical removal and effectiveness of therapy.
【Inspection principle】
The CEA Rapid Test is a one-step chromatographic sandwich immunoassay designed for the quantitative measurement of CEA. The CEA antigen in the sample was first bound with the conjugated compound of fluorescent labeled CEA monoclonal antibody, then moved and combined with another CEA monoclonal antibody fixed on the nitrocellulose membrane, and the double antibody sandwich complex was formed at the detection line of the cellulose nitrate membrane. The quantitative detection results were obtained by NIR-1000 dry fluoroimmunoassay analyser.
【Components】
Name | Quantity | Component |
Test cards | 25 | It is composed of fluorescent pad (coated with fluorescent labeled CEA monoclonal mouse antibody), nitrocellulose membrane (coated with CEA monoclonal mouse antibody and Goat anti mouse IgG antibody), absorbent paper and backing |
Sample diluent | 25(300μL/tube) | Phosphate buffer |
ID card | 1 | With specific stand curve file |
The components in different batches of kits cannot be used interchangeably.
【Storage conditions and validity】
The kit should be stored at 4℃~30℃, out of direct sunlight. It is valid for 18 months. The test card should be used within 15 minutes after unsealing under the environment of 15℃~30℃ and 20% ~ 90% relative humidity.
The production date, batch number and expiration date are shown in the outer package of the product.
【Applicable instruments】
NIR-1000 dry fluoroimmunoassay analyser produced by WWHS Biotech. Inc.
【Sample requirements】
【Procedure】
【Reference interval】
Normal persons who do not smoke: 95% had values less than 5ng/ml. The normal reference value is 5ng/ml in this assay. It is recommended that each laboratory should establish its own normal range based on a representative sampling of the local population.
【Interpretation of results】
【Limitations of methods】
【Performance】
1. Limits of detection
No more than 1ng /ml.
2. Accuracy
The relative deviation from the target value is within ±15%.
3. Precision
The within and between assay coefficient of variations are within 15%.
4. Linear range
Within the linear range (1 ~ 500ng/ml), the linear correlation coefficient R≥0.990.
【Note】
1. This kit is only used for in vitro diagnosis.
2. The test card and sample diluent are disposable and cannot be reused.
3. Please check the integrity and validity of the kit package before use, and then open the package. When it is stored at low temperature, it should be restored to room temperature (15℃ ~ 30℃) before opening the package for use. The reagents with damaged inner package and beyond the validity period cannot be used.
4. The requirements of specimen collection and storage should be strictly observed. If the specimen is turbid, it should be centrifuged and discarded before use.
5. The used kits should be treated as potential infectious substances, and all samples, reagents and potential pollutants should be disinfected and treated according to the relevant local regulations.
Tumor Maker | ||||||
cat#. | Product item | Specimen | Reaction Time | Measure Range | Clinical Range | Itended Use |
20 | AFP | Serum/Plasma | 15min. | 2.5-200ng/ml | <20ng/ml | pregnancy cancer |
21 | CEA | Serum/Plasma | 15min. | 1-200ng/ml | <5ng/ml | colon cancer, colorectal cancer,etc. |
22 | NSE | Serum/Plasma | 15min. | 1-400ng/ml | <16ng/ml | non-small cell lung cancer |
23 | FOB | fecal specimens | 10min. | 50-1000ng/ml | <100ng/ml | Abnormal recessive gastrointestinal bleeding |
24 | PG II | Serum/Plasma | 15min. | 1-100ug/L | PGI/PGII>3.0 | gastric abnormalities |
25 | PG I | Serum/Plasma | 15min. | 2.5-200ug/L | >70ng/ml | gastric abnormalities |
26 | TPSA | Serum/Plasma | 15min. | 0.5-40ng/ml | <4ng/ml | prostate cancer |
27 | FPSA | Serum/Plasma | 15min. | 0.1-10ng/ml | <1ng/ml | prostate cancer |
28 | CA12-5 | Serum/Plasma | 15min. | 20-500U/ml | <35U/ml | ovarian cancer |
29 | CA15-3 | Serum/Plasma | 15min. | 10-400U/ml | < 25 U/mL | breast cancer |
30 | HE4 | Serum/Plasma | 15min. | 50-2000pmol/L | <140 pmol/L | ovarian cancer |
31 | CA19-9 | Serum/Plasma | 15min. | 10-400U/ml | < 27 U/mL | pancreatic cancer |
32 | β-HCG | Serum/Plasma | 15min. | 5-400mIU/ml | <10 mIU/mL | Early pregrancy, ectopic HCG cancer,incomplete abortion |
33 | CK19(Cyfra21-1) | Serum/Plasma | 15min. | 0.5-50ng/ml | <2.5ng/ml | non-small cell lung cancer |
Sample
Requirements
1.
Plasma,
serum
and
whole
blood
can
be
used
as
samples.
The
whole
blood
should
be
collected
in
a
tube
containing
heparin,
citrate
or
EDTA
as
the
anticoagulant.
If
the
serum
procedure
is
used,
collect
blood
in
a
tube
without
anticoagulant
and
allow
clotting.
Hemolyzed
samples
should
not
be
used.
2.
Venous
blood
was
collected
according
to
routine
laboratory
methods
to
avoid
hemolysis.
3.
It
is
highly
recommended
to
use
fresh
samples
instead
of
keeping
the
samples
at
room
temperature
for
a
long
time.
After
samples
were
collected,
the
detection
should
be
completed
within
4
hours
at
room
temperature
(15℃~30℃).
The
whole
blood
sample
can
be
stored
at
2℃~8℃
for
24
hours.
Plasma
and
serum
samples
can
be
stored
at
2℃~
8℃
for
7
days,
-20℃for
30
days.
4.
Before
testing,
the
sample
should
return
to
room
temperature
(15℃~30℃).
The
frozen
samples
should
be
completely
thawed,
rewarming
and
mixed
evenly
before
use.
Repeated
freeze-thaw
cycles
should
be
avoided.
Applicable
Instrument
WWHS
NIR-1000
dry
fluoroimmunoassay
analyser
About
WWHS
Biotech
Inc
WWHS
Biotech.
Inc
Is
A
High-Tech
Enterprise
Incubated
By
The
Research
Institute
Of
Tsinghua
University
In
Shenzhen
In
2016.
The
Company
Is
Located
In
The
National
Biomedical
Industrial
Base
In
Pingshan
District,
Shenzhen,
With
About
32,000
Square
Feet
Space
For
Workshop
And
Office.
As
A
Fast-Growing
Biotechnology
Company,
We
Dedicate
To
The
Development
Of
World-Class
Bio-Detection
Technologies
That
Meet
The
Ever-Increasing
Demands
On
Clinical
Diagnostics.
We
Focus
On
Developing
Cost-Effective
And
Precise
Rapid
Diagnostic
Products
Based
On
Our
Unique
Near
Infrared
(NIR)
Fluorescence
Platform
Technologies
(PGOLD™
And
IR-LF™)
With
Major
Interests
In
Cardiology,
Infectious
Diseases,
Oncology,
Metabolic
Diseases
And
Women
And
Children’s
Health.
FAQ:
Q1:
Are
you
trading
company
or
manufacturer
?
A1:
We
are
manufacturer.
Q2:
Do
you
provide
samples
?
A2:
Yes,we
do
provide
samples.If
you
need
it,
please
contact
us.
Q3:
How
about
the
quality?
A3:
We
have
the
best
professional
engineer
and
strict
QA
and
QC
system
to
ensure
you
get
high
quality
products
from
us.
Q4:
How’s
the
package?
A4:
Normally
are
cartons,
but
also
we
can
pack
it
according
to
your
requirements.
Q5:
How’s
the
delivery
time?
A5:
It
depends
on
the
quantity
you
need.